CCM
ITCI

Coldstream Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Coldstream Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,601
Closed -$211K – 3544
2025
Q1 		$211K Sell
1,601
-1,826
-53% -$228K ﹤0.01% 983
2024
Q4 		$286K Sell
3,427
-24
-0.7% -$1.97K 0.01% 845
2024
Q3 		$255K Buy
3,451
+82
+2% +$6.16K 0.01% 921
2024
Q2 		$231K Sell
3,369
-372
-10% -$25.8K 0.01% 877
2024
Q1 		$259K Buy
3,741
+51
+1% +$3.5K 0.01% 828
2023
Q4 		$264K Buy
+3,690
New +$212K 0.01% 759

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Coldstream Capital Management's ITCI Position: Q2 2025 in Review

Coldstream Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,601 shares — an estimated $211K sold.

Coldstream Capital Management first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $286K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Coldstream Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,601 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $211K.
  • Coldstream Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
  • Coldstream Capital Management's Intra-Cellular Therapies Inc. position peaked at $286K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.